SCHEMBL10135160

SCHEMBL10135160

Fc1cccc(COC2CCCC2)c1F

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CARM1 Q86X55 1/20 0.45
PRMT6 Q96LA8 1/20 0.45
KDM4E B2RXH2 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.40
ALOX5AP P20292 1/20 0.40
FEN1 P39748 1/20 0.40
SLC6A2 P23975 1/20 0.37
SLC6A4 P31645 1/20 0.37
SLC6A3 Q01959 1/20 0.37
SCN9A Q15858 2/20 0.36
SIGMAR1 Q99720 2/20 0.36
DRD4 P21917 1/20 0.36
DCPS Q96C86 1/20 0.35
FFAR4 Q5NUL3 1/20 0.35
IDO1 P14902 2/20 0.35
HTR2A P28223 1/20 0.35
TACR1 P25103 1/20 0.35
HTR1A P08908 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18615766 0.86 CARM1 (0.57) CARM1PRMT6KDM4EL3MBTL1SLC6A2
SCHEMBL3124811 0.85 SLC6A2 (0.46) CARM1PRMT6SLC6A2SLC6A4SLC6A3
SCHEMBL3128158 0.85 CARM1 (0.42) CARM1PRMT6KDM4EL3MBTL1ALOX5AP
SCHEMBL4965091 0.77 KDM4E (0.46) CARM1PRMT6KDM4EL3MBTL1SLC6A2
SCHEMBL10302573 0.77 HCRTR2 (0.41) CARM1PRMT6ALOX5APFEN1SLC6A2
SCHEMBL4965765 0.77 KDM4E (0.43) CARM1PRMT6KDM4EL3MBTL1SCN9A
SCHEMBL10302623 0.76 CARM1 (0.39) CARM1PRMT6ALOX5APFEN1SLC6A2
SCHEMBL31381190 0.75 FFAR4 (0.41) CARM1PRMT6FFAR4
SCHEMBL2459213 0.73 CARM1 (0.41) CARM1PRMT6FFAR4
SCHEMBL5140181 0.73 IDO1 (0.45) ALOX5APFEN1SLC6A2SLC6A4SLC6A3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124636-B2 Imidazolidinone derivatives as 11B-HSD1 inhibitors HOFFMANN-LA ROCHE INC. (US) 2012-02-28 US disclosed
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HOFFMANN-LA ROCHE, INC. 2009-11-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090275573-A1 Imidazolidinone Derivatives as 11B-HSD1 Inhibitors HSD11B1, HSD17B1, HSD17B11 CARM1 984/4885PRMT6 1701/4885KDM4E 1006/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.